We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Roche's Ophthalmology Drug Fails to Meet Primary Endpoint
Read MoreHide Full Article
Roche Holding AG (RHHBY - Free Report) announced that its ophthalmology candidate, lampalizumab, did not meet the primary endpoint in Spectri, the first of two phase III studies.
Roche is evaluating lampalizumab for the treatment of GA due to age-related macular degeneration (AMD).
Following the news, shares of the company dropped about 1.9%. Roche’s shares have underperformed the industry year to date. The stock has been up 10.4% compared with the industry’s gain of 14.8% in the same time frame.
Notably, the Spectri study showed that lampalizumab did not reduce mean change in geographic atrophy (GA) lesion area compared to sham treatment at one year (48 weeks). Furthermore, dosing for patients will be stopped until the results from the second phase III study — Chroma — are evaluated with results expected in November 2017. However, safety profile was in line with previous lampalizumab studies and other intravitreal therapies.
In fact, both Spectri and Chroma are identically-designed, double-masked, global studies evaluating the efficacy and safety of a 10 mg dose of lampalizumab administered every four or six weeks by intravitreal injection versus sham injections in patients with GA due to AMD.
Markedly, the failure of the study is a setback for Roche’s ophthalmology pipeline portfolio.
Another company, Ophthotech Corporation is evaluating its pipeline candidate Fovista in a phase III study (OPH1004) in combination with either Regeneron Pharmaceuticals, Inc.’s (REGN - Free Report) Eylea or Roche’s Avastin versus Eylea or Avastin monotherapy for treating wet AMD.
However, Ophthotech study failed as the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in the study, per data announced last month.
Two other studies on Fovista — OPH1002 and OPH1003 — evaluating Fovista, in combination with Novartis AG’s (NVS - Free Report) Lucentis, for the treatment of wet AMD, had earlier failed to meet the same primary endpoint. The data was announced last year.
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Roche's Ophthalmology Drug Fails to Meet Primary Endpoint
Roche Holding AG (RHHBY - Free Report) announced that its ophthalmology candidate, lampalizumab, did not meet the primary endpoint in Spectri, the first of two phase III studies.
Roche is evaluating lampalizumab for the treatment of GA due to age-related macular degeneration (AMD).
Following the news, shares of the company dropped about 1.9%. Roche’s shares have underperformed the industry year to date. The stock has been up 10.4% compared with the industry’s gain of 14.8% in the same time frame.
Notably, the Spectri study showed that lampalizumab did not reduce mean change in geographic atrophy (GA) lesion area compared to sham treatment at one year (48 weeks). Furthermore, dosing for patients will be stopped until the results from the second phase III study — Chroma — are evaluated with results expected in November 2017. However, safety profile was in line with previous lampalizumab studies and other intravitreal therapies.
In fact, both Spectri and Chroma are identically-designed, double-masked, global studies evaluating the efficacy and safety of a 10 mg dose of lampalizumab administered every four or six weeks by intravitreal injection versus sham injections in patients with GA due to AMD.
Markedly, the failure of the study is a setback for Roche’s ophthalmology pipeline portfolio.
Another company, Ophthotech Corporation is evaluating its pipeline candidate Fovista in a phase III study (OPH1004) in combination with either Regeneron Pharmaceuticals, Inc.’s (REGN - Free Report) Eylea or Roche’s Avastin versus Eylea or Avastin monotherapy for treating wet AMD.
However, Ophthotech study failed as the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in the study, per data announced last month.
Two other studies on Fovista — OPH1002 and OPH1003 — evaluating Fovista, in combination with Novartis AG’s (NVS - Free Report) Lucentis, for the treatment of wet AMD, had earlier failed to meet the same primary endpoint. The data was announced last year.
Roche Holding AG Price
Roche Holding AG Price | Roche Holding AG Quote
Zacks Rank
Roche currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>